Tetracycline complexes with sustained activity

Patent metadata

Field	Value
Publication number	US-12539333-B2
Application number	US-201917289661-A
Country	US
Kind code	B2
Filing date	Oct 29, 2019
Priority date	Oct 29, 2018
Publication date	Feb 3, 2026
Grant date	Feb 3, 2026

Abstract

The present invention generally relates to controlled release of tetracycline antibiotics. Specifically, it relates to a complex comprising a tetracycline compound (TC) or a pharmaceutically acceptable salt, hydrate or solvate thereof and a divalent metal carboxylate; a pharmaceutical preparation comprising the complex, methods for manufacturing the complex and the pharmaceutical preparation, and a complex or a pharmaceutical preparation for use in a method for treatment of the human or animal body, in particular for therapy and/or prophylaxis of a bacterial infection; and/or wherein antibiotic activity is maintained over a prolonged period of time; and/or for the therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.

First claim

The invention claimed is:

1 . A complex formed of a tetracycline compound (TC) or a pharmaceutically acceptable salt thereof and a magnesium carboxylate (MgA 2 ), wherein:
the molar ratio TC:MgA 2 is in the range of 1:0.8-3.0; and A is a carboxylate anion derived from stearic acid (C 18 ), wherein the tetracycline compound (TC) is selected from minocycline and doxycycline.

2 . The complex according to claim 1 having the formula [(TC)·2(MgA 2 )], wherein the tetracycline compound (TC) is minocycline or a pharmaceutically acceptable salt thereof.

3 . A pharmaceutical preparation comprising the complex according to claim 1 and one or more pharmaceutically acceptable excipient(s) comprising at least one or more biodegradable polymer(s), wherein the preparation is selected from the group consisting of extrudate, particle, granule, powder, film, strip, compact, chip, paste, cream, gel, emulsion, suspension, liniment, ointment, balm, topical aerosol, topical solution, topical suspension.

4 . The pharmaceutical preparation according to claim 3 , which is; i) arranged for topical administration; or ii) is an extrudate; or iii) or both.

5 . The pharmaceutical preparation according to claim 3 , wherein i) the one or more biodegradable polymer(s) is selected from biodegradable polyesters, mixed biodegradable polyesters, biodegradable PEGylated diblock (AB) or triblock (ABA or BAB) copolymers, and pectins; or ii) the total content of the tetracycline compound (TC) is in the range of 5-20 wt. %; or iii) both.

6 . The pharmaceutical preparation according to claim 5 , wherein the biodegradable polymer(s): i) have a weight average molecular weight range of 4-250 kDa; ii) have a glass transition temperature of 42-48° C.; iii) have an inherent viscosity [dl/g] (0.1% in CHCl3 at 25° C.) of 0.03-1.70; or iv) are PLGA copolymers (poly(D,L-lactide-co-glycolides)) having a L/G ratio of 5/95-95/5; or v) combinations thereof.

7 . The pharmaceutical preparation according to claim 5 , wherein the biodegradable polymer(s) are PLGA copolymers; i) having a L/G ratio of 25/75-75/25; ii) having a weight average molecular weight range (kDa) of 5-90; iii) having an inherent viscosity [dl/g] (0.1% in CHCl3 at 25° C.) of 0.14-0.82; or iv) being terminated with ester, alkyl ester or PEG groups; v) or combinations thereof.

8 . The pharmaceutical preparation according to claim 5 , wherein the biodegradable polymer(s) are i) poly(D,L-lactide-co-glycolides) with a PLA/PGA ratio of 50:50, having a weight average molecular weight range of 7,000-38,000 or an inherent viscosity [dl/g] (0.1% in CHCl3 at 25° C.) of 0.16-0.44, or both, or ii) poly(D,L-lactide-co-glycolides) with a PLA/PGA ratio of 50:50 and a PEG end group (PLGA-PEG), having a weight average molecular weight range of 30-85 kDa or an inherent viscosity [dl/g] (0.1% in CHCl3 at 25° C.) of 0.45-0.80, or iii) both.

9 . The pharmaceutical preparation according to claim 3 , which is in the form of an extrudate.

10 . The pharmaceutical preparation according to claim 9 , having: i) an essentially circular or an essentially elliptical cross section; or ii) a maximum cross-sectional diameter of 0.1-1 mm; or iii) combinations thereof.

11 . A method for manufacturing the complex according to claim 1 , the method comprising the following steps:
(a) providing a mixture comprising: a tetracycline compound (TC) selected from minocycline and doxycycline and a magnesium carboxylate (MgA 2 ) in a molar ratio of 1:0.8-3.0, wherein A is a carboxylate anion derived from stearic acid (C 18 ), and an organic solvent, wherein the mixture is substantially free of water; (b) heating said mixture to form the complex; and (c) removing the organic solvent to obtain the complex.

12 . A method for manufacturing the pharmaceutical preparation according to claim 9 , the method comprising the following steps, in substantial absence of water:
(d) comminuting the complex according to claim 1 and, if present, one or more pharmaceutically acceptable excipients to obtain an extrusion precursor; (e) extruding said extrusion precursor at a temperature above room temperature; and (f) cooling the product of step (e) to obtain the pharmaceutical preparation in the form of a strand-shaped extrudate.

13 . A method for treatment of a human or animal in need thereof, comprising administering a therapeutically effective amount of the complex according to claim 1 , or a pharmaceutical preparation comprising the complex, to the human or animal, wherein the therapy of (i) a bacterial infection comprising one or more bacteria susceptible to minocycline and/or doxycycline; or (ii) a bacterial infection comprising one or more bacteria selected from the group consisting of Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, Streptococcus gordonii, Fusobacterium nucleatum, Actinomyces naeslundii and Parvimonas micra.

14 . The method according to claim 13 , wherein antibiotic activity is maintained over a period of at least 21 days.

15 . A method for therapy of an acute, chronic or recurrent periodontal disease, the method comprising administering a therapeutically effective amount of the complex according to claim 1 , or a pharmaceutical preparation comprising the complex, to a human or animal in need thereof.

16 . The method according to claim 15 , wherein the periodontal disease is selected from dental plaque-induced gingival diseases, periodontitis, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis associated with endodontic lesions, peri-implant mucositis, peri-implantitis and endodontic infections.

17 . The pharmaceutical preparation according to claim 5 , wherein the biodegradable polyesters are selected from poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polyhydroxybutyric acid (PHB) and polycaprolactone (PCL); the mixed biodegradable polyesters are selected from PLA-PCL and PLGA-PCL; and the biodegradable PEGylated diblock (AB) or triblock (ABA or BAB) copolymers are selected from PEG-PLA, PEG-PLGA, PEG-PCL and PEG-PCL-PLGA.

18 . The method according to claim 15 , wherein the complex, or the pharmaceutical preparation comprising the complex, is administered to one or more of a tooth, gum, and periodontal pocket, of the human or animal.

19 . A pharmaceutical preparation comprising the complex according to claim 1 and a biodegradable polymer, wherein the preparation is an extrudate.

20 . The pharmaceutical preparation according to claim 19 , wherein the total content of the tetracycline compound (TC) is in the range of 5-20 wt. %.

21 . The pharmaceutical preparation according to claim 19 , wherein the biodegradable polymer is selected from biodegradable polyesters, mixed biodegradable polyesters, biodegradable PEGylated diblock (AB) or triblock (ABA or BAB) copolymers, and pectins.

22 . The pharmaceutical preparation according to claim 21 , wherein the biodegradable polymer is a biodegradable polyester selected from poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), polyhydroxybutyric acid (PHB) and polycaprolactone (PCL); the mixed biodegradable polyesters are selected from PLA-PCL and PLGA-PCL; and the biodegradable PEGylated diblock (AB) or triblock (ABA or BAB) copolymers are selected from PEG-PLA, PEG-PLGA, PEG-PCL and

Assignees

• Fraunhofer Ges Forschung

Inventors

• Kiesow Andreas
• Buchholz Mirko
• Sarembe Sandra
• Mäder Karsten
• Kirchberg Martin
• Eick Sigrun

Classifications

• A61K47/69

  the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit · CPC title

• A61K31/65

  Tetracyclines · CPC title

• A61K47/593 Primary

  Polyesters, e.g. PLGA or polylactide-co-glycolide · CPC title

• C07C2603/40

  containing four condensed rings · CPC title

• C07C231/22

  Separation; Purification; Stabilisation; Use of additives (separation of optical isomers C07C231/20) · CPC title